Skip to main content
. Author manuscript; available in PMC: 2021 Dec 15.
Published in final edited form as: Cancer Res. 2021 Apr 5;81(12):3347–3357. doi: 10.1158/0008-5472.CAN-20-3611

Figure 5. NADI-351 selectively targets Notch1-driven cells and tumors.

Figure 5.

(A) FACS sorting of OE33 cells stained with Notch1 Ab. (B) Post-sort analysis of cells gated in (A). (C) Colony formation assays using NADI-351 were performed using each sorted OE33 Notch1 population. Cells were dosed every 48h for 2 weeks with the indicated concentration of NADI-351. (D) Relative Notch target gene expression in Notch1+ and Notch1− cells treated with NADI-351 for 24h (RT-qPCR). (E) FACS analysis of cells from EAC47 PDX tumor stained with Notch1 Ab and treated with 30 mg/kg of NADI-351 daily for 14 days. (F) EAC47 PDX tumors treated with vehicle (DMSO) or 30 mg/kg NADI-351, i.p. daily for 14 days were excised and examined by RT-qPCR for changes in Notch and apoptosis target genes (n=3). Error bars are representative of three independent experiments and indicate mean ± SD. p values ≤ 0.05 are considered statistically significant and indicated by asterisk(s). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.